Overview

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Status:
Recruiting
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate